{"product_id":"macrogenics-bcg-matrix","title":"MacroGenics Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious about MacroGenics' product portfolio? Our BCG Matrix analysis highlights which products are driving growth (Stars), generating consistent revenue (Cash Cows), lagging behind (Dogs), or present potential but require more investment (Question Marks). This snapshot offers valuable directional insight.\u003c\/p\u003e\n\u003cp\u003eTo truly unlock the strategic advantage, purchase the full BCG Matrix report. It provides granular data, detailed quadrant placements, and actionable recommendations to optimize your investment and product development strategies for MacroGenics.\u003c\/p\u003e\n\u003cp\u003eDon't miss out on the complete picture. Get the full BCG Matrix and gain a clear, data-driven understanding of MacroGenics' market position, enabling you to make informed decisions and outmaneuver the competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLorigerlimab (mCRPC)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLorigerlimab, a bispecific PD-1 × CTLA-4 DART molecule, is currently being evaluated in the fully enrolled Phase 2 LORIKEET study for metastatic castration-resistant prostate cancer (mCRPC).  Clinical updates are expected in the latter half of 2025, offering a key data point for its market potential. \u003c\/p\u003e\n\u003cp\u003eGiven the historical challenges in treating mCRPC, lorigerlimab's advancement in this setting indicates significant growth potential.  The drug's success could establish it as a prominent therapy, capitalizing on MacroGenics' advanced DART technology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLorigerlimab (Ovarian Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLorigerlimab is being explored in the LINNET Phase 2 study for platinum-resistant ovarian cancer and clear cell gynecologic cancer, with patient dosing commencing mid-2025. This move targets a significant unmet need in oncology. \u003c\/p\u003e\n\u003cp\u003eThe potential for lorigerlimab in ovarian cancer, a disease with a 5-year survival rate of approximately 30% in its advanced stages, represents a substantial market opportunity. Positive early results from the LINNET study could position this DART asset for considerable future market share and growth within this critical therapeutic area.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMGC026 (B7-H3 ADC)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMGC026 is a promising antibody-drug conjugate (ADC) targeting B7-H3, currently in Phase 1 clinical trials with dose escalation underway. MacroGenics is planning dose expansion for MGC026 in 2025, demonstrating a strategic commitment to this therapeutic approach.\u003c\/p\u003e\n\u003cp\u003eThe company's continued focus on MGC026, even after discontinuing vobra duo, underscores a strong conviction in the significant growth potential of targeting B7-H3. This target is believed to be effective across a range of solid tumors, making MGC026 a key asset in MacroGenics' pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMGC028 (ADAM9 ADC)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMGC028, an antibody-drug conjugate targeting ADAM9, is currently navigating Phase 1 clinical trials. This early-stage development places it within MacroGenics' expanding portfolio of ADCs, a class of therapeutics experiencing significant growth in the oncology market. \u003c\/p\u003e\n\u003cp\u003eThe focus on solid tumors for MGC028 is strategic, as this represents a vast and largely underserved patient population. Success in these trials could unlock substantial market opportunities for MacroGenics. For instance, the global oncology market was valued at over $200 billion in 2023 and is projected to continue its upward trajectory. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eMGC028 targets ADAM9, a protein implicated in tumor growth and metastasis.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCurrently in Phase 1 clinical development for solid tumors.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRepresents a key asset in MacroGenics' growing ADC pipeline.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePositive clinical outcomes could lead to significant market penetration in a high-growth therapeutic area.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary DART Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics' proprietary DART platform is a cornerstone of its high-growth strategy, enabling the development of innovative bispecific antibodies designed for enhanced therapeutic efficacy.\u003c\/p\u003e\n\u003cp\u003eThis platform is a key driver for generating a pipeline of novel product candidates with significant breakthrough potential in oncology. MacroGenics has consistently invested in advancing its DART technology, recognizing its capacity to unlock new treatment paradigms.\u003c\/p\u003e\n\u003cp\u003eThe DART platform's ability to create bispecific antibodies allows for simultaneous targeting of multiple tumor-associated antigens or immune cells, thereby enhancing anti-tumor activity and potentially overcoming resistance mechanisms. This technological advantage positions MacroGenics to capture substantial future market share across a range of oncology indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDART Platform: \u003c\/strong\u003e Enables bispecific antibody development for enhanced oncology treatments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Generation: \u003c\/strong\u003e Drives the creation of novel product candidates with breakthrough potential.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Capture: \u003c\/strong\u003e Positions MacroGenics to secure future market share in diverse oncology indications.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestment Focus: \u003c\/strong\u003e Continuous investment fuels platform advancement and new therapeutic opportunities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics' Pipeline: High-Potential Oncology Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLorigerlimab, targeting mCRPC and ovarian cancer, and MGC026, an ADC for solid tumors, represent MacroGenics' key \"Stars\" due to their significant market potential and ongoing clinical development. MGC028, another ADC in early trials, also shows promise in a high-growth area.\u003c\/p\u003e\n\u003cp\u003eThese assets leverage MacroGenics' DART and ADC technologies, positioning them for substantial future market capture. The global oncology market's continued growth, exceeding $200 billion in 2023, underscores the opportunity for successful therapies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eTarget Indication\u003c\/th\u003e\n\u003cth\u003ePlatform\u003c\/th\u003e\n\u003cth\u003eDevelopment Stage\u003c\/th\u003e\n\u003cth\u003eMarket Potential\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLorigerlimab\u003c\/td\u003e\n\u003ctd\u003emCRPC, Ovarian Cancer\u003c\/td\u003e\n\u003ctd\u003eDART\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMGC026\u003c\/td\u003e\n\u003ctd\u003eSolid Tumors\u003c\/td\u003e\n\u003ctd\u003eADC (B7-H3)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMGC028\u003c\/td\u003e\n\u003ctd\u003eSolid Tumors\u003c\/td\u003e\n\u003ctd\u003eADC (ADAM9)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003eSignificant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe MacroGenics BCG Matrix analyzes its product portfolio by classifying units as Stars, Cash Cows, Question Marks, or Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eMacroGenics BCG Matrix offers a clear, one-page overview of its product portfolio, simplifying strategic decision-making by placing each business unit in its appropriate quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetifanlimab (ZYNYZ®) Milestones and Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics' licensing agreement for Retifanlimab (ZYNYZ®) with Incyte positions it as a strong Cash Cow within their BCG Matrix. This partnership has already yielded substantial financial benefits, with MacroGenics receiving a significant $100 million milestone payment in July 2024. This payment was triggered by positive Phase 3 clinical trial results, underscoring the drug's development progress.\u003c\/p\u003e\n\u003cp\u003eThe ZYNYZ® collaboration is structured to provide ongoing, high-margin revenue streams for MacroGenics. Beyond the recent milestone, the company is eligible for further development, regulatory, and commercial milestones. Additionally, MacroGenics will benefit from tiered royalties on future sales, all without incurring the direct costs associated with commercializing the product themselves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTZIELD® (Teplizumab) Milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTZIELD, a monoclonal antibody developed by MacroGenics and sold to Sanofi, received FDA approval in November 2022 for its potential to delay the onset of type 1 diabetes. This approval positions TZIELD as a significant revenue generator for MacroGenics.\u003c\/p\u003e\n\u003cp\u003eMacroGenics is set to receive substantial remaining milestone payments from its agreement with Sanofi for TZIELD. This stream of non-dilutive income is a prime example of a cash cow, as it leverages past research and development with limited additional investment required from MacroGenics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics' contract manufacturing services are a clear Cash Cow, demonstrating robust growth.  In Q2 2025, this segment generated $15.4 million in revenue, a significant leap from $2.9 million in Q2 2024. This substantial increase highlights the segment's ability to generate consistent and expanding cash flow.\u003c\/p\u003e\n\u003cp\u003eThis strong performance in contract manufacturing underscores its role as a stable cash generator for MacroGenics. The revenue stream effectively utilizes the company's existing manufacturing infrastructure, thereby bolstering financial stability and providing crucial funding for its research and development initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroGenics' strategic shift towards partnership income positions its collaborations as key cash cows.  The company has secured significant funding, including over $1.7 billion in potential milestone payments from major pharmaceutical partners like Gilead, Incyte, and Sanofi. This approach offers a stable financial base and a reliable income stream.\u003c\/p\u003e\n\u003cp\u003eThis partnership strategy effectively mitigates MacroGenics' direct financial exposure. By leveraging the resources and market reach of its collaborators, the company can maximize the potential returns from its innovative drug pipeline without bearing the full cost of late-stage development and commercialization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePartnership Revenue Model:\u003c\/strong\u003e Focus on collaborations for development and commercialization.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMilestone Payments:\u003c\/strong\u003e Over $1.7 billion in potential milestone payments secured from key partners.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRisk Mitigation:\u003c\/strong\u003e Reduced direct financial risk by sharing development and commercialization costs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePredictable Income:\u003c\/strong\u003e Creates a more stable and predictable revenue stream for the company.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExisting Cash Position and Runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroGenics' existing cash position provides significant financial strength. As of June 30, 2025, the company reported $176.5 million in cash and cash equivalents. This robust liquidity is projected to sustain operations through the first half of 2027, offering a substantial runway for continued development. \u003c\/p\u003e\n\u003cp\u003eThis financial stability is a key component of its BCG Matrix, acting as a 'cash cow'. The strong cash position enables disciplined investment in promising programs, supporting ongoing research and development efforts. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eCash Position:\u003c\/strong\u003e $176.5 million as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProjected Runway:\u003c\/strong\u003e Extended through the first half of 2027.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLiquidity Drivers:\u003c\/strong\u003e Milestone payments and cost reduction initiatives.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Role:\u003c\/strong\u003e Serves as a financial 'cash cow' for sustained operations and future development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics: Cash Cow Strategy Fuels Financial Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics' licensing agreement for Retifanlimab with Incyte, along with the Sanofi collaboration for TZIELD, are prime examples of its Cash Cow strategy. These partnerships leverage past R\u0026amp;D investments to generate predictable, high-margin revenue streams through milestone payments and royalties, minimizing MacroGenics' direct commercialization costs.\u003c\/p\u003e\n\u003cp\u003eThe company's contract manufacturing services also significantly contribute to its Cash Cow status, showing remarkable year-over-year revenue growth. This segment capitalizes on existing infrastructure, providing stable cash flow that fuels further innovation and development.\u003c\/p\u003e\n\u003cp\u003eMacroGenics' overall partnership model, aiming for over $1.7 billion in potential milestone payments, alongside a strong cash position of $176.5 million as of June 30, 2025, solidifies its Cash Cow assets. This financial stability ensures operational continuity and supports strategic investments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset\u003c\/td\u003e\n\u003ctd\u003eRevenue Source\u003c\/td\u003e\n\u003ctd\u003eStatus\u003c\/td\u003e\n\u003ctd\u003eKey Financials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetifanlimab (Incyte)\u003c\/td\u003e\n\u003ctd\u003eMilestone Payments \u0026amp; Royalties\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003e$100M milestone in July 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTZIELD (Sanofi)\u003c\/td\u003e\n\u003ctd\u003eMilestone Payments \u0026amp; Royalties\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003eSignificant remaining milestone payments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Manufacturing\u003c\/td\u003e\n\u003ctd\u003eService Revenue\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003e$15.4M revenue in Q2 2025 (vs $2.9M in Q2 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnerships (Gilead, etc.)\u003c\/td\u003e\n\u003ctd\u003ePotential Milestones\u003c\/td\u003e\n\u003ctd\u003eCash Cow Foundation\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1.7B potential milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003eWorking Capital\u003c\/td\u003e\n\u003ctd\u003eFinancial Strength\u003c\/td\u003e\n\u003ctd\u003e$176.5M as of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eMacroGenics BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe BCG Matrix document you are currently previewing is the identical, fully formatted report you will receive immediately after your purchase. This means you'll gain access to the complete analysis without any watermarks or demo content, ready for immediate strategic application. You can trust that what you see is precisely what you'll download, enabling you to seamlessly integrate this powerful business tool into your planning and decision-making processes. This ensures a transparent and efficient acquisition of a valuable strategic resource.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674476626297,"sku":"macrogenics-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/macrogenics-bcg-matrix.png?v=1755790076","url":"https:\/\/portersfiveforce.com\/products\/macrogenics-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}